Havant MP Alan Mak demands to know why Labour Government walked away from £450m AstraZeneca investment deal
Havant MP Alan Mak has demanded to know why the Labour Government chose to walk away from a £450m investment deal with ...
Sumitomo Mitsui Trust Group Inc. Has $5.58 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)
Sumitomo Mitsui Trust Group Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & ...
cambridgeindependent1d
AstraZeneca revenues rise to $54bn as it enters ‘unprecedented’ period for company
AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...
AstraZeneca shares rise as China probe update reassures
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...
Final Trades: Trade Desk, Leidos Holdings, Astrazeneca and Devon Energy
Aerospace startup Boom says they've proven quiet supersonic flight is possible with their passenger airplanes after a ...
AstraZeneca Could Pay $4.5 Million In China Scandal. Here's Why Shares Jumped.
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
The inside story of Britain’s failure to clinch £450mn AstraZeneca deal
How an agreement set up by the Tories and lauded by Labour fell victim to cost-cutting and UK curbs on drugs expenditure ...
AstraZeneca ditches UK investment over cut in state support
AstraZeneca on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in ...
AstraZeneca's cancer drug tops list of new brands launched in 2024
Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...
Down 13% from its year high at £116.50 now, AstraZeneca’s share price looks cheap to me anywhere under £219.81
AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...
UBS raises AstraZeneca stock rating to buy, hikes target
AstraZeneca (NASDAQ:AZN) stock received a positive assessment from UBS, as analyst Matthew Weston upgraded the pharmaceutical giant's rating from Neutral to Buy. The upgrade was accompanied by a ...